Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

NCT02628574 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: TRX518 monotherapy
DRUG: TRX518 with gemcitabine
DRUG: TRX518 with pembrolizumab
DRUG: TRX518 with nivolumab

Sponsor

Leap Therapeutics, Inc.